Walter Reed National Military Medical Center
Bethesda, Maryland, 20889, United States
NCT Number: NCT03907254
Preliminary clinical evidence suggests that Service Members with symptoms of post-traumatic stress disorder (PTSD) or Post Traumatic Stress (PTS) who participate in the Service Dog Training Program (SDTP) report improved physical and psychological outcomes, including those with overlapping symptoms associated with traumatic brain injury (TBI) and post-concussion symptoms (PCS).
This study intends to examine the psychological, social, and biological effects of learning how to train a future service dog combined with standard of care for individuals with symptoms of Post-Traumatic Stress (PTS), including those with overlapping TBI and persistent Post-Concussive Symptoms (PCS). Biological, social, and behavioral measures will be collected throughout study participation.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Bethesda, Maryland, 20889, United States
Preliminary clinical evidence suggests that Service Members with symptoms of post-traumatic stress disorder (PTSD) or Post Traumatic Stress (PTS) who participate in the Service Dog Training Program (SDTP) report improved physical and psychological outcomes, including those with overlapping symptoms associated with traumatic brain injury (TBI) and post-concussion symptoms (PCS). Since 2011, over 3,000 injured Service Members have participated in the SDTP. The program entails teaching Service Members how to train service dogs. Participation in this program helps injured Service Members develop skills, such as attention and discipline, which are needed to successfully shape the dog's behavior and are translatable to other social settings. Further, participation in the program appears to enhance the participants' well-being, quality of life, and relationship with significant others, including their children. Moreover, Service Members (SM) who participate in the SDTP report being motivated to participate in the program for the chance of helping other wounded warriors, who will be the recipients of the dogs that they train.
Despite the reported anecdotal benefits from the SDTP, there has been a lack of prospective controlled research studies that examine the efficacy of the program or the biological basis as to how it may be helpful to improve the underlying disease. This study intends to examine the psychological, social, and biological effects of the SDTP combined with standard of care for individuals with symptoms of Post-Traumatic Stress (PTS), including those with overlapping TBI and persistent Post-Concussive Symptoms (PCS). This study will also seek to identify potential psychological, physiological, and/or biological factors that may influence the degree of response from this noninvasive intervention, as well as its potential impact on disease/symptom modification. Further, for those subjects with family members, it will seek to share data with a parallel study ongoing at the University of Maryland to evaluate the effects of the SDTP on family member stress levels, relationship satisfaction, communication evaluate the effects of the SDTP on family member stress levels, relationship satisfaction, communication and parenting.
To accomplish these aims the researchers will recruit DEERS eligible medical beneficiaries who are experiencing PTS and PCS symptoms. Up to 156 participants will be recruited in the National Capital Region (NCR) for a ten-week longitudinal pre-post study, in which each participant will serve as their own control. Additionally, up to 104 participants will be recruited for a three-week longitudinal parallel randomized study will be available for participants recruited through the National Intrepid Center of Excellence (NICoE) 4-week Intensive Outpatient Program (IOP).
Each participant in the active group will train a service dog using methods that facilitate a relationship between the trainer and dog for the gradual shaping of desired behavior. Self-report measures of behavioral symptoms will be given weekly throughout participation in this study. Biological measures, including blood collection, HR, BP, etc. will be collected at baseline, during the three-week training follow-up, during the six-week training follow-up (NCR participants only), and at a three-month post-training followup (optional for NICoE IOP participants). The researchers will also be collecting self-report assessments from the participant, observational reports from an Occupational Therapist (OT) and electronic health records to track healthcare utilization and social skills (i.e. communication).
The study is being carried out in collaboration with the Center for Neuroscience and Regenerative Medicine (CNRM). Under this collaboration, the study will use the CNRM Core Resources including the CNRM Biorepository. Data stored and shared within the CNRM Data Repository will be coded, and upon destruction of the Master List, de-identified.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will spend one hour, two times a week working with professional service dog trainers in order to shape the dog's behavior for it's future role as a service dog for service members with mobility impairments.
Time frame: The PCL-5 will be collected at screening as part of the inclusion criteria, and subsequently once a week until the end of the 10-week study period, as well as at the 3-month follow-up visit.
A 20-item self-report measure that assesses changes in symptom severity of PTSD to include, monitoring symptom change during/after treatment, screening individuals for PTSD, and making a provisional PTSD diagnosis. This instrument will be used for inclusion criteria for the study as well as to assess change during the course of the study.
Time frame: The GAD-7 will be collected once a week from start of study until the end of the 10-week study period, as well as at the 3-month follow-up visit.
A 7-item self-report measure that assesses an individual's level of anxiety from 0 (least severe) to 21 (most severe). The measure has excellent internal consistency (Cronbach alpha = 0.92) and test-retest reliability (intraclass correlation = 0.83). GAD-7 takes less than 5 minutes to complete.
Time frame: The PHQ-9 will be collected once a week from start of study until the end of the 10-week study period, as well as at the 3-month follow-up visit.
A 9-item measure of depression from 0 (least severe) to 27 (most severe). The measure has excellent internal reliability (Cronbach's alpha = 0.89), and discriminant validity was supported by ROC analyses that indicated area under the curve for the PHQ-9 in diagnosing depression was 0.095.
Time frame: The CD-RISC will be completed at the 4-week, 7-week, 10-week, and 3-month follow-up visits.
A 25-item self-report measure to help quantify resilience and, as a clinical measure, to assess treatment response on a scale from 0 (least resilient) to 100 (most resilient). The measure has high internal consistency (Cronbach's alpha = 0.89) and test-retest reliability (intra-class correlation = 0.87).
Time frame: The DVPRS will be completed at the 4-week, 7-week, 10-week, and 3-month follow-up visits, as well as after each participant training session (twice a week).
A visual pain scale to assess individual's pain intensity on a scale of 0-10 (10 being most severe pain), with an additional 4 questions to assess pain's interference with the participant's activity, sleep, mood, and stress.
Time frame: The PSS will be completed at the 4-week, 7-week, 10-week, and 3-month follow-up visits.
A 10-item measure that assesses an individual's appraisal of their life stressors from 0 (least perceived stress) to 40 (most perceived stress). The PSS demonstrates good reliability (0.84 to 0.86) and face validity, and it is predictive of biological indicators of stress in humans with correlation coefficients ranging from 0.52 to 0.76 for symptomalogical measures.
Time frame: The PSQI will be completed at the 4-week, 7-week, 10-week, and 3-month follow-up visits.
A 19-item self-report measure (with 5 additional questions rated by the bedpartner or roommate) evaluating sleep quality and disturbances with lower scores indicating better sleep. The PSQI demonstrates high internal reliability (Cronbach's alpha = 0.83) and test-retest reliability (r = 0.68 to 0.79).
Time frame: The HRQOL-14 will be completed at the 4-week, 7-week, 10-week, and 3-month follow-up visits.
A 14-item self-report measure that assesses quality of life based on "healthy days" measures and symptoms and activity limitations.
Time frame: Blood will be collected at baseline (Week 0-1), Week 3, Week 6, and at the 3 month follow-up visit.
Blood collection not exceeding 40 mL per time point.
Time frame: Blood will be collected at baseline (Week 0-1), Week 3, Week 6, and at the 3 month follow-up visit.
Blood collection not exceeding 40 mL per time point. Cytokines strongly associated with PTSD and depression include pro-inflammatory factors IFNG, IL-12, IL-6, and TNF alpha. Cytokines will be measured by multiplex or single immunoassays.
Time frame: Blood will be collected at baseline for full genome sequencing.
Blood collection not exceeding 40 mL. DNA genomic variants will be measured by whole genome sequencing.
Time frame: The SDTP Trainer Evaluation Form will be completed by the professional dog trainer after each training session, which occurs twice a week from Week 4 through Week 10.
Questions that will be answered by the dog trainer about the participant. It includes questions about the participant's: level of engagement, ability to understand instruction, ability to communicate instructions praise to the dog, and level of frustration.
Time frame: The LAPS will be collected at Week 4.
A 23-item self-report measure that assesses an individual's attachment to pets with higher scores indicating less attachment to pets. The measure has excellent internal consistency (Cronbach alpha = 0.93).
Time frame: The LEC-5 will be collected at Weeks 4 and 10.
A 17-item self-report measure designed to screen for potentially traumatic events in an individual's lifetime. The LEC-5 assesses exposure to 16 events known to potentially result in PTSD or distress and includes one additional item assessing any other extraordinarily stressful event not captured in the first 16 items.
Time frame: The MOS-SSS will be collected at Week 4 and the 3-month follow-up visit.
A 19-item instrument that assesses perceived social support on a scale from 19 (least social support) to 95 (most social support). The measure is comprised of four support scales, including: emotional/informational, tangible, affectionate, and positive social interaction. The measure has excellent internal consistency (Cronbach alpha = 0.91 to 0.96).
Time frame: The NSI will be collected weekly from start of session through the 10-week training period, and again at the 3-month follow-up visit.
A 22-item measure to assess post-concussive symptoms in individual's who suffered a TBI. The NSI demonstrates high internal consistency (Cronbach's alpha = 0.95).
Time frame: The PAS will be collected at the Week 4 visit.
An 18-item measure to assess human-animal bonding with higher scores indicating a more negative attitude towards pets. The measure has excellent internal consistency (Cronbach alpha = 0.94).
Time frame: The OSU-TBI will be collected at Week 4.
A structured clinical interview that confirms the diagnosis of mTBI and/or multiple concussion/blast exposures.
Time frame: The ACIS will take place at the start of study, then subsequently every 3 weeks until the end of the 10-week training period. It will be administered once more at the 3-month follow-up visit.
An observational assessment that gathers data on communication and interaction skills. The ACIS looks at three domains (physicality, information exchange, and relations) and describe different aspects of communication and interaction.
Time frame: Heart rate will take place at all major study visits (Weeks 4, 7, 10, and 3-month follow-up), as well as during each training session twice a week from Week 4 through Week 10.
Heart rate will be measured using a standard arm cuff.
Time frame: Blood pressure will take place at all major study visits (Weeks 4, 7, 10, and 3-month follow-up), as well as during each training session twice a week from Week 4 through Week 10.
Blood pressure will be measured using a standard arm cuff.
Time frame: Anthropometric data will be collected at Weeks 4, 7, 10, and the 3-month follow-up visit.
Neck, waist, and hip measurements using inches
Time frame: Weight measurements will be collected at Weeks 4, 7, 10, and the 3-month follow-up visit.
Weight measured in pounds.
Time frame: The Qualitative Interview will take place at Week 10 and the 3-month follow-up visit.
The goal of the qualitative portion of this study is to examine the participants' experience with the SDTP. We are interested in identifying and describing which elements of the intervention are most effective in engaging participants and bringing about behavior change as well as which ones are least effective.
Time frame: Healthcare Utilization Records will be updated during the major study visits at Week 0, Week 4, Week 7, Week 10, and the 3-month follow-up visit.
Healthcare utilization records will be collected through review of the participants Electronic Health Records (EHR). Study participants will be reviewed for their number of medical visits.
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03868930
Anxiety Disorders, Behavior
Boston, Massachusetts, United States
View Trial DetailsNCT02709369
Anxiety, Anxiety Disorders
Winston-Salem, North Carolina, United States
View Trial DetailsNCT01816061
Behavior, Brain Diseases
Washington D.C., District of Columbia, United States
View Trial DetailsNCT00676182
Brain Diseases, Brain Injuries
Gainesville, Florida, United States
View Trial Details